-
Mashup Score: 6Radiolabeled GPVI-Fc for PET Imaging of Multiple Extracellular Matrix Fibers: A New Look into Pulmonary Fibrosis Progression - 10 month(s) ago
Invariably fatal and with a particularly fast progression, pulmonary fibrosis (PF) is currently devoid of curative treatment options. Routine clinical diagnosis relies on breathing tests and visualizing the changes in lung structure by CT, but anatomic information is often not sufficient to identify early signs of progressive PF. For more efficient diagnosis, additional imaging techniques were…
Source: Journal of Nuclear MedicineCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities - 1 year(s) ago
We present an overview of our prospective fibroblast-activation protein inhibitor (FAPI) registry study across a 3-y period, with head-to-head comparison of tumor uptake in 68Ga-FAPI and 18F-FDG PET, as well as FAP immunohistochemistry. Methods: This is an interim analysis of the ongoing 68Ga-FAPI PET prospective observational trial at our department. Patients who underwent clinical imaging with…
Source: Journal of Nuclear MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities https://t.co/pn4Ljo7BEP
-
-
Mashup Score: 1Fibroblast Activation Protein–Targeted Radioligand Therapy for Treatment of Solid Tumors - 1 year(s) ago
Fibroblast activation protein (FAP) has received increasing attention as an oncologic target because of its prominent expression in solid tumors but virtual absence from healthy tissues. Most radioligand therapies (RLTs) targeting FAP, however, suffer from inadequate tumor retention or clearance from healthy tissues. Herein we report a FAP-targeted RLT comprising an FAP6 ligand conjugated to DOTA…
Source: Journal of Nuclear MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
Fibroblast Activation Protein–Targeted Radioligand Therapy for Treatment of Solid Tumors https://t.co/6ENiuD12t6
-
-
Mashup Score: 9Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities - 1 year(s) ago
We present an overview of our prospective fibroblast-activation protein inhibitor (FAPI) registry study across a 3-y period, with head-to-head comparison of tumor uptake in 68Ga-FAPI and 18F-FDG PET, as well as FAP immunohistochemistry. Methods: This is an interim analysis of the ongoing 68Ga-FAPI PET prospective observational trial at our department. Patients who underwent clinical imaging with…
Source: Journal of Nuclear MedicineCategories: General Medicine News, Latest HeadlinesTweet-
New imaging method superior for diagnosing multiple types of #cancer, with potential for targeted treatment https://t.co/xa8yZ4zfRO https://t.co/7UlkXZFnov
-
-
Mashup Score: 2
The aim of the current study was to describe the risk of hepatotoxicity for patients with gastroenteropancreatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy (PRRT) with a very high liver tumor burden, defined as tumor involving more than 75% of the liver. Methods: We conducted a retrospective analysis of 371 patients who received at least 1 cycle of 177Lu-DOTATATE at…
Source: Journal of Nuclear MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
PRRT in NET patients with extensive liver involvement...? Safe...? Should we do it...? This study suggests it is safe, even in patients with > 75% liver involvement. Excellent work led by @drjasonstarr and team including @sonbol_bassam and @TubaKendi https://t.co/EmDClQyzJd
-
-
Mashup Score: 32Cure of Disseminated Human Lymphoma with [177Lu]Lu-Ofatumumab in a Preclinical Model - 1 year(s) ago
Although immunotherapies that target CD20 on most non-Hodgkin lymphoma (NHL) cells have improved patient outcomes, current therapies are inadequate because many cases are, or become, refractory or undergo relapse. Here, we labelled the third-generation human anti-CD20 antibody ofatumumab with 177Lu, determined the in vitro characteristics of [177Lu]Lu-ofatumumab, estimated human dosimetry, and…
Source: Journal of Nuclear MedicineCategories: General Medicine News, Latest HeadlinesTweet-
Nuclear medicine therapy cures human #non-Hodgkin'slymphoma in preclinical model https://t.co/ZBwlL1dFIF https://t.co/jjquDzSebC
-
-
Mashup Score: 0Development of a Lensless Radiomicroscope for Cellular-Resolution Radionuclide Imaging - 1 year(s) ago
The action of radiopharmaceuticals takes place at the level of cells. However, existing radionuclide assays can only measure uptake in bulk or in small populations of single cells. This potentially hinders the development of effective radiopharmaceuticals for disease detection, staging, and treatment. Methods: We have developed a new imaging modality, the lensless radiomicroscope (LRM), for…
Source: Journal of Nuclear MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
SCI member @GPratx and others have developed a low-cost imaging modality, the lensless radiomicroscope, that can visualize the distribution of medical #radiopharmaceuticals with very fine resolution. https://t.co/NyAXSFzeP5 https://t.co/YkdxD1RJAm
-
-
Mashup Score: 1Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3–Expressing Liver Cancer by Immuno-PET - 1 year(s) ago
Primary liver cancer is the third leading cause of cancer-related deaths, and its incidence and mortality are increasing worldwide. Hepatocellular carcinoma (HCC) accounts for 80% of primary liver cancer cases. Glypican-3 (GPC3) is a heparan sulfate proteoglycan that histopathologically defines HCC and represents an attractive tumor-selective marker for radiopharmaceutical imaging and therapy for…
Source: Journal of Nuclear MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @freddyeescorcia: Link to pull paper: https://t.co/AaN4CSJjpQ
-
-
Mashup Score: 0Summary: Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol - 1 year(s) ago
PET imaging with 16α-18F-fluoro-17β-fluoroestradiol (18F-FES), a radiolabeled form of estradiol, allows whole-body, noninvasive evaluation of estrogen receptor (ER). 18F-FES is approved by the U.S. Food and Drug Administration as a diagnostic agent “for the detection of ER-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.” The Society of Nuclear…
Source: Journal of Nuclear MedicineCategories: Latest Headlines, Oncologists2Tweet-
Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol https://t.co/AiC1R8o5oQ
-
-
Mashup Score: 2Molecular imaging of pulmonary inflammation in electronic and combustible cigarette users: a pilot study - 1 year(s) ago
Electronic cigarette (EC) use has increased dramatically, particularly among adolescents and young adults, which, like cigarette use, can cause pulmonary inflammation and increase the risk of lung disease. Methods: This preliminary study used positron emission tomography with 18F-6-(1/2)(2-fluoro-propyl)-4-methylpyridin-2-amine (18F-NOS) to quantify inducible nitric oxide synthase (iNOS)…
Source: Journal of Nuclear MedicineCategories: General Medicine News, Latest HeadlinesTweet-
PET imaging shows greater lung #inflammation in e-cigarette users than #cigarettesmokers https://t.co/6igWojcudQ https://t.co/6z5Gy9VLCi
-
Novel #imagingagent allows for earlier detection of progressive #pulmonaryfibrosis https://t.co/wTBaGd84pg https://t.co/J0HAfdtMDH